Kevin Bitterman, Director at Genocea Biosciences, holds 1.15M shares in Disc Medicine (Ticker: IRON), holds 2.52M shares in Akero Therapeutics (Ticker: AKRO), holds 4.16M shares in Editas Medicine (Ticker: EDIT). Most recently, Kevin Bitterman Bought ― shares of Disc Medicine on Jun 20, 2024 for an estimated value of 8.00M.
What is the percentage of profitable transactions made by Kevin Bitterman?
The percentage of profitable transactions made by Kevin Bitterman is 47%.
What is the average return per transaction made by Kevin Bitterman?
The average return per transaction made by Kevin Bitterman is -16.50%.
What stocks does Kevin Bitterman hold?
Kevin Bitterman holds: GNCAQ, EDIT, AKRO, IRON stocks.
What was Kevin Bitterman’s latest transaction?
Kevin Bitterman latest transaction was an Informative Buy of $8.00M.
What was Kevin Bitterman's most profitable transaction?
Kevin Bitterman’s most profitable transaction was an Informative Buy of IRON stock on June 20, 2024. The return on the trade was 57.50%.
What is Kevin Bitterman's role in Genocea Biosciences?
Kevin Bitterman's role in Genocea Biosciences is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.